Interest of a 6-month depot form of hormonotherapy in the treatment of advanced hormone dependent prostate cancer: Results from the 'ELIRE' observational study;Intérêt d'une forme semestrielle d'hormonothérapie pour le traitement du cancer de la prostate hormono-dépendant à un stade avancé: Résultats d'ELIRE, enquête observationnelle française

Progres en Urologie

Volumn 21, Issue 12, 2011, Pages 866-874

  Ouzaid, I ^a   Roupret M ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

GHRH agonists; Hormonotherapy; Prostate cancer; Quality of life

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; BIOLOGICAL MARKER; DRUG DERIVATIVE; GONADORELIN; LEUPRORELIN; LUPROLIDE ACETATE GEL DEPOT; PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; BLOOD; CANCER GRADING; CANCER STAGING; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; FOLLOW UP; FRANCE; HEALTH CARE SURVEY; HUMAN; MALE; NEOPLASM; PATHOLOGY; PROSTATE TUMOR; QUALITY OF LIFE; QUESTIONNAIRE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BIOLOGICAL MARKERS; DELAYED-ACTION PREPARATIONS; FOLLOW-UP STUDIES; FRANCE; GONADOTROPIN-RELEASING HORMONE; HEALTH CARE SURVEYS; HUMANS; LEUPROLIDE; MALE; NEOPLASM GRADING; NEOPLASM STAGING; NEOPLASMS, HORMONE-DEPENDENT; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 80955144127     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.purol.2011.07.006     Document Type: Article

References (20)

1. Rebillard X., Grosclaude P., Lebret T., Patard J.J., Pfister C., Richaud P., et al. Projection de l'incidence et de la mortalité par cancer urologique en France en 2010. Prog Urol 2010, 20(S4):211-214.
2. Sharifi N., Gulley J.L., Dahut W.L. Androgen deprivation therapy for prostate cancer. JAMA 2005, 294:238-244.
3. Rossi D., Cornu J.N., Roupret M. De l'œstrogénothérapie aux agonistes de la LHRH. Prog Urol 2007, 17(S2):287-290.
4. Heidenreich A., Bellmunt J., Bolla M., Joniau S., Mason M., Matveev V., et al. EAU Guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011, 59:61-71.
5. Salomon L., Azria D., Bastide C., Beuzeboc P., Cormier L., Cornud F., et al. Recommandations en onco-urologie 2010: cancer de la prostate. Prog Urol 2010, 20(S4):217-251.
6. Tolis G., Ackman D., Stellos A., Mehta A., Labrie F., Fazekas A.T., et al. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc Natl Acad Sci U S A 1982, 79:1658-1662.
7. Villers A., Haffner J., Taibi A., Lucas C., Wibault P. Prise en charge thérapeutique de l'adénocarcinome de la prostate localement avancé en France. Enquête observationnelle OCTAVE. Prog Urol 2006, 16:316-319.
8. HAS: AMM Eligard 45mg. Accès le19/12/2010. http://www.has-sante.fr/portail/upload/docs/application/pdf/ct-5253_eligard_.pdf.
9. Schulman C., Alcaraz A., Berges R., Montorsi F., Teillac P., Tombal B. Expert opinion on 6-monthly luteinizing hormone-releasing hormone agonist treatment with the single-sphere depot system for prostate cancer. BJU Int 2007, 100(S1):1-5.
10. Crawford E.D., Sartor O., Chu F., Perez R., Karlin G., Garrett J.S. A 12-month clinical study of LA-2585 (45.0mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol 2006, 175:533-536.
11. Bolla M., Van Tienhoven G., Warde P., Dubois J.B., Mirimanoff R.O., Storme G., et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 2010, 11:1066-1073.
12. Alibhai S.M., Breunis H., Timilshina N., Johnston C., Tomlinson G., Tannock I., et al. Impact of androgen-deprivation therapy on physical function and quality of life in men with nonmetastatic prostate cancer. J Clin Oncol 2010, 28:5038-5045.
13. McLeod D.G. Hormonal therapy: historical perspective to future directions. Urology 2003, 61(S1):3-7.
14. Talcott J.A. Androgen deprivation as primary treatment for early prostate cancer: should we "just do something"? J Natl Cancer Inst 2002, 94:407-409.
15. Potosky A.L., Knopf K., Clegg L.X., Albertsen P.C., Stanford J.L., Hamilton A.S., et al. Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study. J Clin Oncol 2001, 19:3750-3757.
16. Stephens R.J., Dearnaley D.P., Cowan R., Sydes M., Naylor S., Fallowfield L. The quality of life of men with locally advanced prostate cancer during neoadjuvant hormone therapy: data from the Medical Research Council RT01 trial (ISRCTN 47772397). BJU Int 2007, 99:301-310.
17. Song L., Northouse L.L., Braun T.M., Zhang L., Cimprich B., Ronis D.L., et al. Assessing longitudinal quality of life in prostate cancer patients and their spouses: a multilevel modeling approach. Qual Life Res 2011, 20(3):371-381.
18. Schag C.A., Ganz P.A., Wing D.S., Sim M.S., Lee J.J. Quality of life in adult survivors of lung, colon and prostate cancer. Qual Life Res 1994, 3:127-141.
19. Talcott J.A., Clark J.A. Quality of life in prostate cancer. Eur J Cancer 2005, 41:922-931.
20. Albertsen P.C., Aaronson N.K., Muller M.J., Keller S.D., Ware J.E. Health-related quality of life among patients with metastatic prostate cancer. Urology 1997, 49:207-216.